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Abstract (250 words) 
 
Background. Elevated heart rate in stable coronary artery disease (CAD) is associated 
with worse outcomes, particularly increased risk of myocardial infarction. Heart rate 
reduction with the If inhibitor ivabradine confers symptomatic benefits in angina 
pectoris, and reduces coronary events in patients with stable CAD and left 
ventricular (LV) systolic dysfunction with resting heart rate ≥70 bpm. SIGNIFY is 
testing the hypothesis that heart rate reduction using ivabradine reduces mortality 
and cardiovascular events in patients with stable CAD, but without clinical heart 
failure. 
Methods SIGNIFY is a randomized, double-blind, parallel-group, placebo-controlled, 
event-driven study in patients with stable CAD (1139 centers, 51 countries). 
Participants are aged ≥55 years, with stable CAD and LV ejection fraction >40%, in 
sinus rhythm, with baseline resting heart rate ≥70 bpm, and with at least one 
additional cardiovascular risk factor. At inclusion, patients receive ivabradine 7.5 mg 
bid or matching placebo, which is adjusted at every visit to a heart rate target of 60 
bpm. Participants should receive the best possible background treatment for stable 
CAD. The primary endpoint is a composite of cardiovascular death or nonfatal 
myocardial infarction.  
Results Recruitment lasted from October 2009 to April 2012. SIGNIFY has recruited 
19 102 patients (age 65.0±7.2 years, resting heart rate 77.2±7.0 bpm, 72% male) 
with no evidence for LV dysfunction (ejection fraction, 56.5±8.6%). 
Conclusion SIGNIFY is expected to shed further light on the role of heart rate 
lowering with ivabradine in patients with stable CAD without clinical heart failure. 
The study is expected to end in 2014. 
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Introduction 
 
Coronary artery disease (CAD) is highly prevalent and affects between a quarter and 
a third of the population aged >60 years.1 Despite major advances in therapy in the 
last four decades, which have contributed to substantial declines in both morbidity 
and mortality, patients with stable CAD still have poor outcomes, possibly due to 
unfavorable trends in some risk factors, such as rising obesity and diabetes2 or 
increased prevalence of smoking among younger women. Elevated heart rate has 
been shown to be a risk marker in the general population and in patients with 
cardiovascular disease,3-6 and is now recognized as a modifiable risk factor in heart 
failure.7 In line with this, current guidelines recommend reducing resting heart rate 
to 55 to 60 bpm for the prevention of ischemia and angina in patients with chronic 
stable angina.8 The ongoing SIGNIFY (Study assessIng the morbidity–mortality 
beNefits of the If inhibitor ivabradine in patients with coronarY artery disease) trial 
was designed to test the hypothesis that heart rate lowering with ivabradine reduces 
cardiovascular event rates in patients with stable CAD. In this article, we describe the 
rationale and design of SIGNIFY, as well as the baseline characteristics of the 
population. 
 
Rationale  
 
Elevated heart rate has a range of negative pathophysiological effects in stable CAD, 
all of which contribute to the development and progression of the disease.3,4 
Increased heart rate is associated with an imbalance in myocardial oxygen supply 
and demand, with increased oxygen consumption and decreased perfusion time. 
These effects may lead to myocardial ischemia, which manifests as angina pectoris or 
myocardial infarction (MI). Beyond myocardial ischemia, elevated heart rate may 
have a direct impact on the arterial wall, exerting local hemodynamic forces with an 
adverse effect on the endothelium due to increased exposure to cyclical stress. This 
increases arterial stiffness and promotes atherosclerosis. High heart rate has been 
associated with increased risk of coronary plaque disruption,9 possibly because 
elevated heart rate increases exposure to low shear stress, which is a powerful local 
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stimulus for the development and progression of early stable atherosclerotic plaque 
to high-risk vulnerable plaque. Continued altered shear stress can lead to expansive 
vascular remodeling and plaque progression with intensive lipid accumulation, 
inflammation, and a thin fibrous cap. Endothelial shear stress plays a prominent role 
in the atherogenic process, as confirmed by a recent report of the changes in 
coronary plaque and arterial remodeling in acute coronary syndrome patients.10 This 
report was particularly striking since the observations were made in CAD patients 
followed clinically over 1 year after their acute coronary syndrome, during which 
time they were aggressively managed with vasculoprotective agents. Finally, since 
wall motion is highest at high heart rates, this increases the exposure of vulnerable 
plaque to these detrimental stresses, making the coronary arteries even more 
susceptible to plaque rupture.9 These effects combine to increase the risk for 
adverse clinical outcomes in CAD. 
 
The relationship between elevated heart rate and events in stable CAD appears to be 
particularly strong for MI, as was first documented in patients with CAD and LV 
dysfunction in BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor 
ivabradine in patients with coronary disease and left-ventricULar dysfunction).11 In 
the placebo group of that study, patients with heart rate ≥70 bpm were at 46% 
greater risk for fatal and nonfatal MI (p=0.0066) and a 34% greater risk for 
cardiovascular death (p=0.0041) than patients with heart rate <70 bpm. BEAUTIFUL 
suggested that heart rate 70 bpm is a potential threshold above which patients with 
stable CAD are at higher risk of cardiovascular events.  
 
Lowering heart rate may therefore be expected to reduce mortality and 
cardiovascular event rates in patients with stable CAD.5-12 So far, this has proved 
difficult to demonstrate, partly because most agents that lower heart rate, such as β-
blockers and non-dihydropyridine calcium channel blockers, also have other 
cardiovascular effects, which may be confounding factors. The If inhibitor ivabradine 
lowers heart rate via specific modulation of the activity of the pacemaker cells in the 
sinoatrial node, and has no direct effect on other cardiac parameters, notably 
myocardial contractility, cardiac output,13 and coronary hemodynamics. In the 
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clinical setting, heart rate reduction with ivabradine confers symptomatic benefits in 
patients with angina pectoris, in monotherapy and in combination with β-blocker 
therapy,14,15 and has been demonstrated to improve prognosis in chronic systolic 
heart failure.16 
 
As regards prognosis in stable CAD, although treatment with ivabradine did not 
affect the primary endpoint overall in the BEAUTIFUL trial, it did reduce coronary 
events in a prespecified subgroup of patients with stable CAD and LV systolic 
dysfunction and elevated heart rate (≥70 bpm).17 The reduction in coronary events 
with ivabradine was particularly marked in a post hoc analysis of BEAUTIFUL patients 
with limiting symptoms of angina pectoris at baseline (equivalent to Canadian 
Cardiovascular Society [CCS] classes II and III).18 On the other hand, ivabradine's 
prognostic benefits in CAD patients without LV systolic dysfunction have never been 
formally tested. The SIGNIFY study was set up with the hypothesis that heart rate–
lowering with ivabradine would reduce mortality and cardiovascular events in 
patients with stable CAD, but without clinical heart failure.  
 
SIGNIFY study design 
 
SIGNIFY is an international, multicenter, randomized, double-blind, parallel-group, 
placebo-controlled, event-driven study in patients with stable CAD. The study is 
ongoing in 1139 centers in 51 countries worldwide. The study is being performed 
according to the principles laid out in the Declaration of Helsinki (1964, and its text 
revisions), and approval has been obtained from ethics committees in all countries 
concerned. SIGNIFY is registered on www.controlled-trials.com (ISRCTN61576291). 
 
The main inclusion and exclusion criteria are listed in Table 1. Participants were aged 
≥55 years with documented stable CAD, but no evidence of heart failure (LV ejection 
fraction >40%). Participants had to be in sinus rhythm with resting heart rate ≥70 
bpm measured by standard 12-lead electrocardiography (ECG) in two consecutive 
recordings performed >5 minutes apart. They also had at least one major or two 
minor cardiovascular risk factors (Table 1). Patients could be excluded at the end of 
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run-in, if they had an unstable cardiovascular condition, had compliance of <70% 
during placebo run-in, or failed to confirm eligibility. All participants gave written 
informed consent. 
 
After a single-blind run-in period of 14 to 30 days with placebo, eligible patients 
were randomly allocated to receive ivabradine or placebo; randomization was 
carried out via an interactive response system (voice or web). The double-blind 
period is expected to last between 18 and 48-60 months, and the study plan includes 
visits at 1, 2, 3, and 6 months, and at 6-monthly intervals thereafter (Figure 1).  
 
At inclusion, patients received ivabradine 7.5 mg bid or matching placebo, except for 
patients aged ≥75 years, who were initiated at 5 mg bid. At every subsequent visit, 
resting heart rate is measured by 12-lead ECG (two consecutive recordings 
performed >5 minutes apart) and the study treatment adjusted accordingly with a 
target heart rate of 60 bpm. Thus, patients with heart rates >60 bpm receive the 
next highest dosage (maximum 10 mg bid or matching placebo); patients with heart 
rates 50 to 60 bpm are maintained on the same dosage; and patients with heart 
rates <50 bpm or with signs or symptoms of bradycardia receive the next lowest 
dosage (minimum 5 mg bid or matching placebo). In patients already on 5 mg bid, 
study treatment is stopped if heart rate is <45 bpm or if there are signs or symptoms 
of bradycardia. Patients with heart rate between 45 and 50 bpm on 5 mg bid and no 
signs or symptoms of bradycardia are invited for a control visit within 1 week and 
then stop study drug if heart rate remains <50 bpm. Patients and investigators are 
blinded to treatment allocation, and study drug and placebo have identical 
appearance, though the actual dosage of ivabradine or matched placebo is not 
blinded.  
 
All participants are expected to be treated with guidelines-directed background 
cardiovascular medication. The dosage of background therapy (notably, β-blocker) 
should be optimized prior to selection, and investigators are encouraged to make 
every effort to keep it stable throughout the study. Prohibited treatments include 
strong cytochrome P450 3A4 inhibitors, such as some macrolide antibiotics, 
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antiretroviral drugs (e.g. ritonavir, nelfinavir), systemic azole antifungal agents, and 
nefazodone. Treatments known to increase the QT interval are not recommended 
with ivabradine and should be monitored carefully if administered concomitantly. 
Other heart rate–lowering agents (e.g., β-blockers and non-dihydropyridine calcium 
channel blockers) are allowed, but introduction of such an agent after the beginning 
of the study is discouraged unless clinically indicated. 
 
The investigation schedule is shown in Figure 1. Baseline assessments include 
verification of inclusion criteria, record of medical history, clinical examination, 
concomitant treatments, and smoking habits; evaluation of cardiac parameters 
(resting heart rate [ECG], CCS class, New York Heart Association [NYHA] class, supine 
blood pressure, and LV ejection fraction [echocardiography]); measurement of 
laboratory parameters (blood sample); and recording of adverse events. All of these 
parameters are measured at every subsequent visit, with the exception of LV 
ejection fraction (baseline only), laboratory parameters (at 3 and 12 months, and at 
yearly intervals thereafter), and smoking habits (yearly intervals). Compliance is 
measured at every post-baseline visit by tablet counts. 
 
The primary endpoint of SIGNIFY is a composite of cardiovascular death or nonfatal 
MI. Secondary endpoints include: all-cause death, cardiovascular death, coronary 
death, nonfatal MI, coronary revascularization, elective coronary revascularization, 
and new onset or worsening heart failure. There are also six secondary composite 
endpoints: fatal or nonfatal MI; fatal or nonfatal MI or coronary revascularization; 
fatal or nonfatal MI, coronary revascularization, or unstable angina; cardiovascular 
death, nonfatal MI, or nonfatal stroke; coronary death or nonfatal MI; and nonfatal 
MI, coronary revascularization, or unstable angina. These outcomes will be analyzed 
on a time-to-first event basis. All endpoints are adjudicated by an independent 
Endpoint Validation Committee (definitions of endpoints used by the adjudicators 
are provided in supplementary material). 
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SIGNIFY study organization 
 
The Executive Committee is responsible for the development of the protocol and its 
amendments, and the scientific and clinical conduct of the study. The Steering 
Committee represents the trial investigators and comprises the national study 
coordinators. They approve the protocol and its amendments. The Endpoint 
Validation Committee reviews and adjudicates all pre-specified endpoints using 
blinded data according to definitions laid out in a charter. The Independent Data 
Monitoring Committee evaluates unblinded efficacy and safety data during the 
study. Members of the committees are listed in the Appendix at the end of this 
paper. 
 
Statistical issues 
 
Randomization was stratified by center and angina status (whether or not patients 
were CCS class II or higher). 1070 primary events are necessary to detect a difference 
between the time to first primary endpoint distributions of placebo and ivabradine 
groups, assuming a 5% type I error rate, 90% power, and an expected relative risk 
reduction of 18%. A sample size of 11 330 patients was initially considered sufficient 
to reach this target assuming an annual incidence of the primary composite endpoint 
of 4.5% in the placebo group and a mean follow-up of 2.5 years. Blinded interim 
evaluation in the overall population was carried out in June 2011 and this indicated 
that the annual incidence of the primary composite endpoint was around 2.5%  
giving an estimate of 2.7% in the placebo group on the assumption of a relative risk 
reduction of 18%. On the basis of this revised incidence, the sample size was revised 
to 16 850 patients and the recruitment period was extended (2.5 years instead of 2 
years) giving, with the desired minimal follow-up of 18 months, an expected mean 
follow-up duration of 2.75 years. This sample size takes into account the non-
cardiovascular deaths and consent withdrawals (same initial assumptions of annual 
overall incidence of 1% for each event). The actual mean duration of follow-up may 
be extended or reduced to achieve the planned number of events.  
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The main analysis will be based on the intention-to-treat principle, and in terms of 
time to first event. The superiority of ivabradine versus placebo will be tested on the 
primary composite endpoint using a Cox’s proportional hazard model, adjusted for 
the presence of angina pectoris at baseline (CCS class II or higher). The type I error 
will be set at 5% (two-sided) for all statistical tests, and estimates of hazard ratios 
and 95% confidence intervals will be provided. Similar analyses will be performed for 
the individual components of the primary composite endpoint, as well as the 
secondary endpoints. Analyses are also planned in a subgroup of the population with 
angina pectoris at baseline (CCS class II or higher).  
 
Baseline characteristics are summarized as mean (standard deviation) for continuous 
variables and count (percentage) for categorical variables. All analyses will be 
performed on adjudicated endpoints. Statistical analyses will be performed by the 
independent Robertson Centre for Biostatistics, University of Glasgow, UK. 
 
In addition to reviewing the efficacy and safety data, the Data Monitoring 
Committee will conduct two formal interim analyses to determine if there is 
overwhelming evidence for benefit or harm that might require the study to be 
terminated prematurely. These analyses will take place when 35% and 60% of the 
expected primary endpoint events have occurred. A recommendation for early 
termination of the study on the basis of benefit will be considered if ivabradine is 
superior to placebo on the primary endpoint with a two-sided p-value ≤0.001. 
 
SIGNIFY substudies 
 
The SIGNIFY study has three planned substudies: 
• The Quality of Life Substudy plans to evaluate changes in the Seattle Angina 
Questionnaire in 4500 patients with angina pectoris at baseline (CCS class II 
or higher).  
• The Biomarkers Substudy has the objective of detecting changes in circulating 
von Willebrand factor, as well as high-sensitivity troponin T and other 
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biomarkers of CAD progression and endothelial function, in a group of 380 
patients. 
• The Pharmacogenomics Substudy will analyze whether genetic variations in 
candidate genes and in the whole genome are associated with clinical 
outcomes in about 5000 patients. 
 
Baseline characteristics 
 
Recruitment into SIGNIFY started in October 2009 and the last patient was 
randomized in April 2012. The baseline characteristics of the 19 102 randomized 
patients included in the trial are presented in Table 2. The mean age of the 
randomized population was 65.0±7.2 years with a mean resting heart rate of 
77.2±7.0 bpm, and 72% of the participants were male. In terms of cardiovascular risk 
factors, a considerable proportion of the population had angina pectoris (CCS class II 
or higher) (63%) or a history of MI (73%). About a quarter of the population were 
current smokers (24%). A large proportion had other cardiovascular risk factors, 
notably hypertension (86%), dyslipidemia (71%), or diabetes mellitus (43%). In line 
with the inclusion criteria, a substantial proportion of the population cumulated risk 
factors, for instance, 22% had both diabetes and angina pectoris (CCS class II or 
higher). There was no evidence for LV systolic dysfunction (mean ejection fraction, 
56.5±8.6%) or clinical heart failure. The SIGNIFY population was well treated in terms 
of background cardiovascular medication at baseline, particularly for antithrombotic 
agents (98%), statins (92%), angiotensin-converting enzyme inhibitors (59%), 
angiotensin receptor blockers (23%), and β-blockade (83%). 
 
Discussion 
 
SIGNIFY has enrolled a population of patients with stable CAD, resting heart rate ≥70 
bpm and LV ejection fraction >40%, and with no evidence for heart failure, but with 
relatively high rates of cardiovascular risk factors, most notably hypertension (86%), 
angina pectoris (63%), diabetes (43%), and current smoking (24%). This is a 
particularly relevant population in the light of the known beneficial impact of 
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ivabradine in patients with stable CAD, LV dysfunction, and heart rate ≥70 bpm in 
BEAUTIFUL,17 as well as in a subgroup of BEAUTIFUL patients with angina pectoris.18 
Furthermore, recent observational studies, the EUROASPIRE (European Action on 
Secondary and Primary Prevention by Intervention to Reduce Events)19 and 
COURAGE (Clinical Outcomes Utilizing Revascularization and AGgressive drug 
Evaluation),20 reported that cardiovascular risk factors remain highly prevalent in 
patients with stable CAD, and also that there is imperfect achievement of risk factor 
control. Resting heart rate stands as an easily modifiable parameter that could 
improve risk assessment and management of patients with cardiovascular disease. 
 
The characteristics of the SIGNIFY population are broadly similar to those of patients 
included in international registries in CAD. The SIGNIFY population is comparable to 
the CAD population in REACH (REduction of Atherothrombosis for Continued 
Health)21 and patients with heart rate ≥70 bpm in the CLARIFY (prospeCtive 
observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) 
registry,22 though they are generally of higher risk (for example, higher rates of 
smoking, angina, hypertension, and diabetes), in line with SIGNIFY inclusion criterion 
of additional cardiovascular risk factors. Similarly, differences between the 
characteristics of the SIGNIFY population and that of the Euro Heart Survey of stable 
angina23 also highlight the higher risk profile of the SIGNIFY population, as well as 
changes in contemporary background treatments in the decade since that survey 
was performed. 
 
An important feature of SIGNIFY is that it is designed to test prospectively the 
concept of titration of heart rate lowering therapy to a predefined heart rate target 
of 60 bpm. The target of 60 bpm was selected as it is well established to prevent 
ischemia and is currently included in guidelines for the prevention of ischemia and 
angina in patients with stable CAD.8 Other studies have suggested a better prognosis 
in CAD patients achieving heart rates of 55-60 bpm.12 SIGNIFY is therefore setting 
out to explore questions surrounding which level of heart rate requires treatment, 
and what should be changed in the management of patients with stable CAD to 
improve their prognosis.  
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The primary endpoint of SIGNIFY, a composite of cardiovascular death or nonfatal 
MI, is noteworthy in view of the strong relationship between heart rate and MI. The 
results are therefore expected to shed further light on the role of heart rate in the 
underlying pathophysiology of CAD, as well as the role of pharmacological heart rate 
lowering with the If inhibitor ivabradine in patients with stable CAD and no signs of 
heart failure. 
 
The SIGNIFY trial is currently ongoing. This event-driven trial is expected to end in 
2014. 
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Figure 1. Study design. 
*Patients aged ≥75 years were initiated at 5 mg bid. 
CCS, Canadian Cardiovascular Society. NYHA, New York Heart Association. 
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Table 1. Main inclusion and exclusion criteria in the SIGNIFY study. 
 
Inclusion criteria 
• Male or female, aged ≥55 years 
• Evidence for coronary artery disease:  
 Previous myocardial infarction (≥3 months); or 
 Evidence for multivessel disease irrespective of revascularization status (last coronary 
revascularization ≥3 months if any); or 
 Evidence for non-revascularized single-vessel disease with a positive non-invasive stress 
test, or hospital discharge with documented unstable angina 1 to 12 months previously 
• In sinus rhythm, with resting heart rate ≥70 bpm (standard 12-lead electrocardiogram) 
• Without left ventricular systolic dysfunction (left ventricular ejection fraction>40%) 
• Ambulatory patients in a stable condition with respect to angina (≥1 month) and on 
appropriate and stable doses of conventional cardiovascular medication (≥1 month) 
• Additional cardiovascular risk factors 
 At least one major cardiovascular risk factor:  
o Angina pectoris in Canadian Cardiovascular Society class II or higher (≥1 month); or 
o Objective evidence of myocardial ischemia with moderate to large deficit induced 
by noninvasive stress testing (≤12 months) in patients who did not undergo 
subsequent revascularization; or 
o Hospital discharge after a major coronary event ≤12 months (acute myocardial 
infarction ≥3 months, or unstable angina ≥1 month) 
 Or at least two minor cardiovascular risk factors: 
o Low high-density lipoprotein cholesterol (<40 mg/dL); and/or high low-density 
lipoprotein cholesterol (>160 mg/dL despite lipid-lowering treatment); or 
o Type 1 or 2 diabetes mellitus; or 
o Peripheral artery disease; or 
o Current smoker (≥10 cigarettes per day); or 
o Age ≥70 years 
• Informed consent 
Exclusion criteria 
• Recent myocardial infarction, coronary revascularization, stroke, or transient ischemic attack 
(≤3 months); or with a transplanted heart, implanted pacemaker, implantable cardioverter 
defibrillator, or cardiac resynchronization therapy 
• Scheduled for coronary revascularization; or likely to require surgery for valvular disease 
• Permanent atrial fibrillation or flutter 
• Sick sinus syndrome, sinoatrial block, congenital long QT, 2nd degree and complete 
atrioventricular block. 
• Severe or uncontrolled hypertension; or hypotension 
• Heart failure (New York Heart Association class II or higher, or hospitalization for heart failure 
≤12 months) 
• Requirement for treatments prohibited during the study 
• Current treatment with ivabradine, or known hypersensitivity to ivabradine 
• Abnormal serum creatinine (>200 µmol/L), transaminases (>3 × ULN), or hemoglobin (men, 
<110 g/L, or women, <100 g/L) 
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Table 2. Baseline characteristics 
Values are means±SD or n (%). 
ACE, angiotensin converting enzyme. CCB, calcium channel blocker. CCS, Canadian Cardiovascular 
Society. MRA, mineralocorticoid receptor antagonist.NYHA.  
 
 Whole 
population 
(N=19 102) 
  Whole 
population 
(N=19 102) 
Demographic characteristics      
Age (years) 65.0±7.2  Ethnic origin  
• <70 years 13 669 (72%)  • Caucasian 15 533 (81%) 
• ≥70 years 5433 (28%)  • Asian 2547 (13%) 
• ≥75 years 2228 (12%)  • Other 1021 (5%) 
Body mass index (kg/m2) 28.8±4.6  Systolic blood pressure (mm Hg) 130.5±13.6 
Heart rate (bpm) 77.2±7.0  Diastolic blood pressure (mm Hg) 78.2±8.2 
Male 13 840 (72%)    
     
Cardiovascular risk factors and medical history 
Coronary artery disease duration (years) 6.1±6.3  Dyslipidemia (%) 13 622 (71%) 
Previous myocardial infarction 13 986 (73%)  Diabetes mellitus (%) 8216 (43%) 
Previous coronary revascularization 12 882 (67%)  Peripheral artery disease (%) 3963 (21%) 
Angina status   Current smoker (%) 4610 (24%) 
• No angina symptoms 4812 (25%)  Hypertension (%) 16 409 (86%) 
• CCS class I  2241 (12%)  Left ventricular ejection fraction (%) 56.5±8.6 
• CCS class II to IV 12 049 (63%)  Stroke (%) 1245 (7%) 
     
Concomitant treatments     
Antithrombotic agents 18 646 (98%)  Calcium channel blockers 5864 (31%) 
Statins 17570 (92%)  Diuretics (excluding MRA) 5769 (30%) 
Beta-blockers 15 873 (83%)  MRA 936 (5%) 
ACE inhibitors  11 318 (59%)  Organic nitrates 7560 (40%) 
Angiotensin II receptor blockers 4469 (23%)  Antidiabetic agents 7571 (40%) 
 
